Assoc. Prof. Dr. Hany Fayed | Pharmacology | Best Researcher Award

Posted on 03/05/202503/05/2025 by Academic achievements

Assoc. Prof. Dr. Hany Fayed | Pharmacology | Best Researcher Award

Assoc. Prof. Dr. Hany Fayed | Pharmacology – Associate professor at National Research Centre, Egypt

Dr. Hany Moawad Ali Fayed is an Associate Professor of Pharmacology and Toxicology at the Medical Research and Clinical Studies Institute, National Research Centre (NRC), Egypt. With a remarkable academic background and over a decade of research experience, Dr. Fayed is widely recognized for his groundbreaking work in the fields of pharmacology and toxicology, especially in the study of liver diseases and hepatotoxicity. His research has contributed extensively to understanding the therapeutic potential of various compounds in treating liver fibrosis and related disorders, leading to significant advancements in both academic and clinical settings. Throughout his career, he has demonstrated a keen ability to integrate teaching with research, mentoring students while simultaneously pushing forward innovative scientific research. His publications and contributions to major international journals showcase his dedication to advancing pharmacological and toxicological knowledge.

Profile Verified:

Orcid | Google Scholar

Education:

Dr. Fayed’s academic journey began with a Bachelor of Veterinary Medical Sciences from Menofiya University, Egypt, where he graduated with distinction in 2007. He then pursued a Master’s degree in Veterinary Pharmacology at Cairo University, where he developed a keen interest in hepatoprotection and toxicology, culminating in his thesis on the hepatoprotective effects of artichoke extract against hepatocellular carcinoma in rats. His pursuit of excellence led him to a Ph.D. in Veterinary Pharmacology from Cairo University in 2017, where his dissertation focused on the evaluation of osteopontin in liver fibrosis, a study that significantly advanced the understanding of liver fibrosis mechanisms. Dr. Fayed’s robust educational background laid a solid foundation for his continued work in pharmacology and toxicology, making him a recognized expert in the field.

Experience:

Dr. Fayed’s professional experience spans over a decade, during which he has held pivotal positions in academia and research. From 2012 to 2022, he contributed as an educator at Cairo University, teaching pharmacological and toxicological experiments to veterinary students. This role allowed him to merge his passion for research with his dedication to training future scientists. Since 2015, Dr. Fayed has served as a researcher at the Medical Research and Clinical Studies Institute at NRC, progressing to an Associate Professor in 2023. Throughout his tenure at NRC, he has led various high-impact research projects and contributed to advancing pharmacological therapies, particularly in liver diseases and fibrosis. His involvement in both independent and collaborative research efforts has led to significant findings, reinforcing his position as a leader in his field.

Research Interest:

Dr. Fayed’s primary research interests are centered around pharmacology, toxicology, and liver diseases, with a focus on liver fibrosis, hepatotoxicity, and the molecular mechanisms of pharmacological agents. His recent research includes exploring the therapeutic effects of Canagliflozin and Linagliptin in liver carcinogenesis and the role of natural products in mitigating liver damage. He is also deeply involved in investigating the signaling pathways involved in liver fibrosis, such as AMPK/YAP/TAZ, IL-6/STAT3, and NRF2/HO-1, and their potential as therapeutic targets. His work on natural products, like Sansevieria species, also underscores his commitment to exploring alternative therapies for liver protection. Dr. Fayed’s interdisciplinary research is shaping the future of pharmacology and toxicology, providing essential insights into the treatment of liver diseases.

Award:

Dr. Fayed’s academic and professional excellence has not gone unnoticed. He was honored with the prestigious National Research Centre Prize for the Best Ph.D. Thesis in the Medical Division in 2017-2018. This recognition is a testament to his exceptional research contributions to the field of pharmacology and toxicology, particularly in the study of liver fibrosis. Additionally, Dr. Fayed’s continued success in securing research grants and leading innovative projects reflects his sustained contribution to scientific advancement. His recognition by both national and international bodies highlights his reputation as a highly respected researcher in the field.

Publications:

Dr. Fayed has an extensive publication record in reputable scientific journals. Notable publications include:

“Hepatoprotective Effect of Artichoke Extract Against Pre-cancerous Lesions of Hepatocellular Carcinoma in Rats” (2014), Life Science Journal.
This study explored the protective effects of artichoke extract against liver cancer, contributing to the growing body of research on natural hepatoprotective agents.
“Molecular Mechanisms Underlying Hepatoprotective Effects of Artichoke Extract” (2014), World Journal of Pharmacy and Pharmaceutical Sciences.
This paper delves into the biochemical pathways through which artichoke extract modulates liver damage, establishing it as a key area for further research.
“Mesalazine: The Potential Prophylactic and Remedial Roles in Induced Liver Fibrosis in Rats” (2018), Chemico-Biological Interactions.
This publication highlighted the therapeutic potential of Mesalazine in treating liver fibrosis, demonstrating its role in combating liver damage.
“Targeting AngII/AT1R Signaling Pathway by Perindopril Inhibits Ongoing Liver Fibrosis in Rat” (2019), Journal of Tissue Engineering and Regenerative Medicine.
This research provided insights into the pharmacological mechanisms of Perindopril in mitigating liver fibrosis, showing its clinical potential.
“Metabolomic Profiling of Sansevieria trifasciata and Hepatoprotective Effect in Liver Fibrosis” (2021), Egyptian Journal of Chemistry.
This study explored the hepatoprotective effects of Sansevieria species and their biochemical properties, offering new avenues for natural liver therapies.
“Rosuvastatin Restrains Liver Fibrosis: Involvement of NF-κB and Nrf2/HO-1 Pathways” (2022), International Journal of Veterinary Science.
This publication investigated the therapeutic potential of Rosuvastatin in treating liver fibrosis, contributing to the understanding of its molecular mechanisms.
“Erythropoietin Suppresses Hepatic Fibrosis Caused by Thioacetamide: Role of PI3K/Akt and TLR4 Signaling Pathways” (2023), Oxidative Medicine and Cellular Longevity.
This paper presented novel insights into the use of Erythropoietin for treating hepatic fibrosis, particularly in relation to key cellular signaling pathways.

Conclusion:

Dr. Hany Moawad Ali Fayed’s contributions to pharmacology and toxicology, particularly in liver disease research, demonstrate his unwavering commitment to advancing science. His work has provided critical insights into the molecular mechanisms behind liver fibrosis and hepatotoxicity, making him a leading figure in the field. Through his numerous publications, award-winning research, and dedication to teaching and mentoring, Dr. Fayed continues to shape the future of pharmacological sciences. His achievements are a testament to his expertise and passion for research, positioning him as an outstanding candidate for the “Best Researcher Award.”

Stuart Maudsley | Pharmacology | Best Researcher Award

Posted on 18/03/202518/03/2025 by Academic achievements

Prof. Dr. Stuart Maudsley | Pharmacology | Best Researcher Award

Prof. Dr. Stuart Maudsley | Pharmacology – Professor at Moffitt Cancer Center, United States

Dr. Stuart Russell Maudsley is an esteemed researcher and principal investigator whose work has had a profound impact on the field of pharmacology, particularly in the study of G-protein-coupled receptors (GPCRs). His career has been marked by significant contributions to cancer research, aging, and molecular gerontology, leading to the development of innovative therapeutic strategies aimed at treating complex human diseases. Dr. Maudsley’s work focuses on the precision targeting of GPCRs to develop treatments for a wide range of conditions, from cancer to neurodegenerative disorders, with a unique approach that blends basic science with clinical applications. He has been instrumental in leading transformative research at Moffitt Cancer Center and has earned widespread recognition for his contributions in both academia and industry.

Profile:

Scopus

Education:

Dr. Maudsley earned his Ph.D. in Pharmacology from the University of Leeds, UK, after completing a First-Class Bachelor’s degree in Pharmacology at the same institution. His doctoral research focused on electrophysiological and molecular biological studies of Tachykinin receptors, which set the stage for his continued exploration of receptor biology. His academic journey laid the groundwork for a career dedicated to uncovering the complex molecular mechanisms that regulate cellular behavior and how these processes can be manipulated for therapeutic purposes. His early education and research provided a foundation for his later innovations in the field of pharmacology and receptor therapeutics.

Experience:

Dr. Maudsley’s career spans several prestigious roles that highlight his leadership and expertise in pharmacology and receptor biology. He currently serves as the principal investigator at Moffitt Cancer Center, where he directs the Maudsley Lab, focusing on receptor biology and cancer therapeutics. His work is particularly notable for its precision in targeting GPCRs to treat cancer and other complex diseases. Dr. Maudsley also co-founded HeptOME – Receptor Therapeutics, and his position as a Special Science Advisor for the Belgian Superior Health Council reflects his international influence. His experience in both academic and industry settings has allowed him to bridge the gap between cutting-edge research and real-world therapeutic solutions.

Research Interests:

Dr. Maudsley’s primary research interest lies in the molecular and pharmacological study of GPCRs, a class of receptors that play a crucial role in various cellular processes. He focuses on understanding how these receptors regulate human diseases, particularly cancer, aging, and neurodegenerative disorders. By investigating the intricate mechanisms of GPCR signaling, Dr. Maudsley aims to develop novel targeted therapies that can improve treatment outcomes in these complex diseases. His research extends to systems pharmacology, which integrates multidimensional approaches to identify new drug targets and improve therapeutic strategies. Dr. Maudsley is particularly interested in the therapeutic application of GPCR-targeted medicines and their potential to treat diseases with unmet medical needs.

Awards:

Dr. Maudsley has received numerous accolades for his pioneering research in pharmacology and receptor biology. His work has been consistently recognized for its potential to revolutionize therapeutic strategies for cancer and aging-related diseases. He has been invited to speak at prestigious international conferences and has received several awards from scientific and medical societies for his contributions to understanding receptor biology. His recognition as a co-founder of HeptOME – Receptor Therapeutics further highlights his entrepreneurial spirit and ability to translate scientific discoveries into practical applications that benefit patients worldwide.

Publications:

Dr. Maudsley has an extensive publication record, contributing to major scientific journals and collaborative research projects. A few notable publications include:

Maudsley S., Leysen H., van Gastel J., Martin B. (2021). Systems Pharmacology: Enabling Multidimensional Therapeutics, Reference Module in Biomedical Sciences.
Maudsley S., Schrauwen C., Harputluoğlu İ., Walter D., Leysen H., McDonald P. (2023). GPR19 Coordinates Multiple Molecular Aspects of Stress Responses Associated with the Aging Process, Int J Mol Sci.
Schreurs G., Maudsley S., Nast C., Praet M., Da Silva Fernandes S., Boor P., D’Haese P., De Broe M.E., Vervaet B.A. (2023). Chronic Dehydration Induces Injury Pathways in Rats, Sci Rep.
Maudsley S., Leysen H., Walter D., Vandoren R. (2023). GPCRs Regulate DNA Integrity, Encyclopedia – Biochemistry and Molecular Biology.
Coppens V., De Wachter O., Goossens J., Hendrix J., Maudsley S., Azmi A., van Gastel J., Van Saet A., Lauwers T., Morrens M. (2020). Profiling of Peripheral Blood Mononuclear Cells for Schizophrenia Biomarkers, Neuropsychobiology.
Van Meenen J., Leysen H., Chen H., Baccarne R., Walter D., Martin B., Maudsley S. (2022). Making Biomedical Sciences Publications More Accessible for Machines, Med Health Care Philos.
Leysen H., Maudsley S., Van Gastel J., Martin B. (2021). The RXFP3 Receptor is a Modulator of Aging-Related Disease, Int J Mol Sci.

Conclusion:

Dr. Stuart Russell Maudsley’s extensive contributions to pharmacology, especially in the area of GPCRs and their role in complex diseases, make him an exceptional candidate for the Best Researcher Award. His research, which bridges the gap between basic science and clinical applications, continues to shape the future of precision medicine. Through his innovative work at Moffitt Cancer Center and his involvement in entrepreneurial ventures like HeptOME – Receptor Therapeutics, Dr. Maudsley has made a lasting impact on both academia and industry. His leadership in the field and his commitment to advancing therapeutic solutions for cancer, aging, and neurodegenerative diseases position him as a truly deserving nominee for this prestigious award.